Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Xilis is raising $16,514,618.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Xiling Shen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xilis
Cancer is the second leading cause of death in the U.S. and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine aims to select the most effective treatments for patients, but existing approaches only benefit a minority of patients. Xilis is developing next generation MicroOrganoSphereTM technologies to guide precision therapy for cancer patients and accelerate drug discovery.

To learn more about Xilis, visit http://www.xilis.net/

Contact:
Xiling Shen, Chief Executive Officer
984-377-6738
xiling.shen@xilis.net
https://www.linkedin.com/in/xiling-shen-75816b2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved